58 results found.
      
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Anika Therapeutics Reports 3Q18 Revenue of $24.1MM, +0.4% vs. 3Q17
Anika Therapeutics posts 3Q18 orthobiologic revenue of $24.1MM, +0.4% vs. 3Q17.
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Anika Therapeutics 2Q18 Orthobiologics Revenue +7% YoY
Anika Therapeutics posted 2Q18 orthobiologic revenue of US $26.2MM, +7.0% vs. 2Q17 and 1H18 revenue of
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Anika Therapeutics Reports 1Q18 Orthobiologic Revenue
Anika Therapeutics posted 1Q18 orthobiologic revenue of US $19.5MM, -3.6% vs. 1Q17.
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Anika Therapeutics' 4Q17 and 2017 Orthobiologic Revenue
Anika Therapeutics posted 4Q17 orthobiologic revenue of US $25.1MM, +3.1% vs. 4Q16, and 2017 revenue of
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
Anika Therapeutics 3Q17 Revenue +7% vs. 3Q16
Anika Therapeutics posted 3Q17 orthobiologic revenue of US $24.0MM, +7.0% vs. 3Q16, and year-to-date revenue of
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
Anika Therapeutics Posts Orthobiologics Sales Growth for 2Q17/1H17
Anika Therapeutics posted 2Q17 orthobiologic revenue of US $24.5MM, +5.0% vs. 2Q16, and 1H17 revenue of
Anika Therapeutics to Log $5MM Milestone Payment for MONOVISC
Anika Therapeutics will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement
Public and Private Company Revenue Review: 1Q17
By Julie A. Vetalice We're eager to see 2Q17 results to prepare a 1H review for you. In the interim, here are the 1Q17 numbers for publicly-traded companies, with updates and estimates for a number of privately-traded companies, too. Exhibits 1 and 2 illustrate 1Q17 performanc...
Anika Therapeutics Posts 1Q17 Orthobiologic Revenue
Anika Therapeutics posted 1Q17 orthobiologic revenue of US $20.2MM, +3.3% vs. 1Q16. 
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
Anika Therapeutics 4Q16 and 2016 Revenue
Anika Therapeutics posted 2016 orthobiologic revenue of US $89.7MM, +22.5% vs. 2015, with 4Q16 revenue of $24.4M...
Company Revenue 3Q16: A Final Look
By Julie A. Vetalice As we wrap up orthopaedic revenue for the latest reporting period, we observe that Stryker and Zimmer Biomet lead the largest orthopaedic companies in 3Q16 growth:
Anika Therapeutics Reports 3Q16 Orthobiologic Revenue
Anika Therapeutics posted 3Q16 orthobiologic revenue of US $22.4MM, +9.6% vs. 3Q15.
Company Revenue Update, 1H16
By Julie A. Vetalice We complete our coverage of 1H16 revenue in this issue. Stryker and Smith & Nephew lead the top five in growth, with 1H16 performance in the low-single-digits compared to 1H15. DePuy Synthes and Zimmer Biomet reported
Anika Therapeutics Posts 2Q16 Orthobiologic Revenue
Anika Therapeutics posted 2Q16 orthobiologic revenue of US $23.3MM, +20.9% vs. 2Q15, as-reported.
Anika Therapeutics Posts 1Q16 Revenue
Anika Therapeutics posted 1Q16 orthobiologic revenue of US $19.6MM, +63.5% vs. 1Q15, as-reported.
Sanofi Reports 1Q16 Synvisc Revenue
Sanofi posted 1Q16 Synvisc viscosupplementation product revenue of €88.0MM (~US $100.7MM), +3.5% from 1Q15, as-reported...
Anika Therapeutics Posts 4Q15/2015 Revenue
Anika Therapeutics posted 4Q15 orthobiologics revenue of US $21.5MM, +63% vs. 4Q14, and 2015 revenue of $73.2M...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group